Bookmark

CLARIFICATION

Schwartz, Jules I.; Nelson, Lois A.
Pediatric Asthma, Allergy & Immunology , Volume 2 (2) Mary Ann LiebertJan 1, 1988

Preview Only

CLARIFICATION

Abstract

LETTERS TO THE EDITOR CLARIFICATION Dr. Weinberger's comments certainly identify a number of variables that can influence the effects of theophylline. We would like to respond to those that Dr. Weinberger specifically stated as potential factors causing a deviation in our results'" from those of his group.'2» Our dosing titration procedure was very similar to that described by the Weinberger group.'2' In fact, in some cases it was even more conservative and would not explain the differences in the results of the two studies. Because it is possible that parents can be the source of drug administration problems in children, we assessed the reliability of the parents with respect to dosing instructions and actual administration. The product formulation issue is certainly important, and we indeed selected only those brands known to be reliable sustained-release formulations.'3-4» The timing of blood samples for theophylline level determinations was appropriate for the release characteristics of the formulation selected. The purpose of our study is to identify potential association of theophylline with central nervous system stimulation in young children. We continue to respect the role of theophylline as an important therapeutic agent in the management of chronic asthma. We appreciate the opportunity to
Loading next page...
1 Page

Preview Only. This article cannot be rented because we do not currently have permission from the publisher.

 
/lp/mary-ann-liebert/clarification-O61YSS0wbM
Title
CLARIFICATION
Author(s)
Schwartz, Jules I.; Nelson, Lois A.
Journal
Pediatric Asthma, Allergy & Immunology , Volume 2 (2) Mary Ann Liebert – Jan 1, 1988
Publisher
Mary Ann Liebert, Inc.
Copyright
Copyright 1988 Mary Ann Liebert, Inc.
Subject
LETTERS TO THE EDITOR
ISSN
0883-1874
eISSN
1557-7767
D.O.I.
10.1089/pai.1988.2.88
Publisher site
Get PDF